Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
19 March 2012 |
Main ID: |
EUCTR2008-004460-39-DE |
Date of registration:
|
11/09/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette Disorder according to DSM-IV criteria
|
Scientific title:
|
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette Disorder according to DSM-IV criteria |
Date of first enrolment:
|
11/11/2008 |
Target sample size:
|
54 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004460-39 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Germany
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Male or female patients ages 6 years-17 years; 2. Written informed consent provided by the patient’s parent (or legal guardian) and assent provided by the patient consistent with ICH/GCP and Local Institutional Review Board requirements for children obtained prior to any study procedures being performed; 3. Ability and willingness to comply with study treatment regimen and to attend study assessments; 4. Diagnosed with Tourette’s Disorder as per the below DSM-IV criteria and with a score =22 on the Total Tic Score (TTS) of the YGTSS at baseline: • Both multiple motor and one or more vocal tics have been present at some time during the illness, although not necessarily concurrently. (A tic is a sudden, rapid, recurrent, non-rhythmic, stereotyped motor movement or vocalization.) • The tics occur many times a day (usually in bouts) nearly every day or intermittently throughout a period of more than 1 year, and during this period there was never a tic-free period of more than 3 consecutive months • The onset is before age 18 years • The disturbance is not due to the direct physiological effects of a substance (e.g., stimulants) or a general medical condition (e.g., Huntington’s disease or post-viral encephalitis) • The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning 5. Diagnosis of Tourette’s Disorder when administering the Diagnostic Interview Schedule for Children (DISC-IV); 6. Women of childbearing potential must have a negative serum Beta-HCG pregnancy test at the Screening (Baseline) visit unless surgically sterile; 7. Either a de novo patient (not on current treatment for TS), or a patient who has been diagnosed with TS, but who the investigator feels, has not been adequately managed using current therapy, or has failed current therapy, whereby the patient may benefit in the use of pramipexole and, if on current therapy, can be safely discontinued from such therapy prior to enrollment into this study; 8. Women of childbearing potential must be using a medically accepted contraceptive method. Acceptable methods of birth control are limited to: Intra-Uterine Device (IUD), oral, implantable, injectable contraceptives and estrogen patch, double barrier method (spermacide + diaphragm), or abstinence at the discretion of the investigator; 9. Having a body weight =20 kg. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Any women of childbearing potential having a positive serum pregnancy test at screening; 2. Clinically significant renal disease or serum creatinine out of this range: 0.3-1.0 mg/dL for patients aged 6-12 years and 0.5-1.4 mg/dL for patients aged 13+ years; 3. Any of the following lab results at screening: ? Hemoglobin (Hgb) below lower limit of normal (LLN) which is determined to be clinically significant. ? Basal thyroid stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significantly (at the investigator’s discretion) out of normal range at screening (if not caused by substitution therapy according the investigator’s opinion). ? Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigator’s discretion. 4. Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, pulmonary disease (such as severe asthma) in the opinion of the investigator which would preclude the patient from participating in this study; 5. History of schizophrenia or any psychotic disorder, history of mental disorders or any present Axis I psychiatric disorder according DSM IV (using the DISC-IV assessment interview) requiring any medical therapy except for TS, except for patients with a diagnosis of ADHD or OCD who are not on therapy; 6. History of/or clinical signs of epilepsy or seizures other than fever related seizures in early childhood; 7. History of/or clinical signs of any malignant neoplasm including suspicious undiagnosed skin lesion (which may be melanoma), melanoma, or a history of melanoma; 8. Any other conditions that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health hazard for the patient; 9. Allergic response to pramipexole or the inactive ingredients in its tablet formulation; 10. Had previous treatment with dopamine agonists other than pramipexole within 14 days prior to baseline visit; 11. Had any other medical treatment for TS besides the study medication within 28 days prior to baseline visit (14 days for guanfacine and clonidine; 14 days for dopamine agonists; 14 days for L-Dopa); 12. Had withdrawal symptoms of any medication at screening or at the baseline visit; 13. Having a K BIT2 IQ score <70 at screening; 14. Having a CY-BOCS score >15 at baseline; 15. Patients who meet criteria for Restless Legs Syndrome and/or Periodic Limb Movement disorder; 16. Patients with a history of severe asthma or pulmonary complications. Patients with asthma that is well-controlled are not excluded; 17. Patients that have initiated psychotherapy for Tourette Syndrome, OCD or ADHD within 3 months prior to starting the trial; 18. Patients receiving psychological, cognitive and/or behavioral treatments greater than 3 months prior to starting the trial for Tourette Syndrome, OCD and/ or ADHD symptoms who will have changes in their treatment plan or treatment course during the trial as well as those patients who will require the initiation of such treatments during the trial. 19. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to start of this study.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Tourette's Syndrome MedDRA version: 9.1
Level: LLT
Classification code 10044127
Term: Tourette's syndrome
|
Intervention(s)
|
Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: pramipexole dihydrochloride monohydrate Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.0625 (salt)- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
Trade Name: Sifrol Product Name: Sifrol Product Code: SND 919 CL2 Y Pharmaceutical Form: Tablet INN or Proposed INN: pramipexole dihydrochloride monohydrate Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.125 (salt)- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
Trade Name: Sifrol Product Name: Sifrol Pharmaceutical Form: Tablet INN or Proposed INN: pramipexole dihydrochloride monohydrate Current Sponsor code: SND 919 CL2 Y Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25 (salt)- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Primary end point(s): Change from baseline of the TTS of the YGTSS after 6 weeks of treatment.
|
Secondary Objective: Secondary efficacy measures: YGTSS, total score; TTS of the YGTSS; CGI-I responder rate; CGI-S; PGI-I responder rate. Safety measures: Incidence of adverse events, proportion of withdrawals due to adverse events, vital signs, weight, ECG assessments as well as safety laboratory parameters. The following additional assessments will be included to further assess the safety of study medication: DuPaul ADHD rating scale IV; Child Depression Inventory-Short Version (CDI-S); The Child Behavior Checklist (CBCL) for 6-18 year olds; The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS); Tanner Staging; MASC.
|
Main Objective: The primary objective of this trial is to evaluate the safety and efficacy of the non ergot dopamine agonist pramipexole for the treatment of tics in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Disorder according to DSM-IV criteria. The primary efficacy measure will be the Total Tic Score (TTS) of the YGTSS at 6 weeks.
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|